USFDA Clears Smith+Nephew's Stemless Shoulder Implant for AETOS System

Smith+Nephew, the worldwide medical technology firm, announces it has obtained 510(k) authorization from the United States Food & Drug Administration for a stemless anatomical total shoulder for the AETOS Shoulder System (AETOS Stemless). AETOS Stemless meets the increasing need for anatomic total shoulder replacement while requiring minimal space in the operating room, facilitating an effective procedure. It aims to enhance metaphyseal stability and fixation through an inlay collar, cruciate fins, and a porous titanium coating that promotes biological fixation.

Launched last year, the AETOS Shoulder System offers a sophisticated design and an enhanced experience thanks to its simplicity, consistency, and versatility. The innovative stemless implant enhances the AETOS Shoulder System range, allowing seamless transition from Stemless to Meta Stem.

“AETOS Stemless represents a significant advancement in shoulder arthroplasty, underscoring our commitment to superior patient outcomes and driving progress in the field of orthopaedic surgery. We are excited to continue unveiling future technologies that will reshape the treatment of shoulder conditions,” said Craig Gaffin, president of global orthopaedics for Smith+Nephew. “With AETOS Stemless, we’re now able to further personalize surgery, providing options that help surgeons give patients the best chance for recovery and a return to living their Life Unlimited.”

Total shoulder arthroplasty is rapidly becoming one of the largest sectors in Orthopaedics, with projections indicating around 250,000 surgeries per year in the US by 2025.